Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | BX-912 | 3 | 72 | 0.001 | 4039.3 | 3895.0 | 1175.8 | -3.0 | 1.040 | 1.040 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 0.0032 | 3914.5 | 3895.0 | 1175.8 | -2.49 | 1.010 | 1.010 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 0.01 | 3926.5 | 3895.0 | 1175.8 | -2.0 | 1.010 | 1.010 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 0.032 | 4025.3 | 3895.0 | 1175.8 | -1.49 | 1.040 | 1.030 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 0.1 | 3944.5 | 3895.0 | 1175.8 | -1.0 | 1.010 | 1.010 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 0.32 | 3819.3 | 3895.0 | 1175.8 | -0.495 | 0.977 | 0.981 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 1.0 | 2373.0 | 3895.0 | 1175.8 | 0.0 | 0.501 | 0.609 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | BX-912 | 3 | 72 | 3.2 | 1936.8 | 3895.0 | 1175.8 | 0.505 | 0.335 | 0.497 | 1.728 | BT549 BX912 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 0.001 | 3191.0 | 3936.8 | 1175.8 | -3.0 | 0.773 | 0.811 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 0.0032 | 3845.0 | 3936.8 | 1175.8 | -2.49 | 0.973 | 0.977 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 0.01 | 3945.0 | 3936.8 | 1175.8 | -2.0 | 1.000 | 1.000 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 0.032 | 3569.0 | 3936.8 | 1175.8 | -1.49 | 0.891 | 0.907 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 0.1 | 3850.3 | 3936.8 | 1175.8 | -1.0 | 0.975 | 0.978 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 0.32 | 3783.3 | 3936.8 | 1175.8 | -0.495 | 0.955 | 0.961 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 1.0 | 3713.8 | 3936.8 | 1175.8 | 0.0 | 0.934 | 0.943 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | Alpelisib | 3 | 72 | 3.2 | 3331.8 | 3936.8 | 1175.8 | 0.505 | 0.817 | 0.846 | 1.743 | BT549 BYL719 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 0.001 | 4042.0 | 4010.0 | 1175.8 | -3.0 | 1.010 | 1.010 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 0.0032 | 3810.0 | 4010.0 | 1175.8 | -2.49 | 0.943 | 0.950 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 0.01 | 3897.0 | 4010.0 | 1175.8 | -2.0 | 0.968 | 0.972 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 0.032 | 3809.3 | 4010.0 | 1175.8 | -1.49 | 0.943 | 0.950 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 0.1 | 3982.5 | 4010.0 | 1175.8 | -1.0 | 0.992 | 0.993 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 0.32 | 3713.3 | 4010.0 | 1175.8 | -0.495 | 0.915 | 0.926 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 1.0 | 3522.3 | 4010.0 | 1175.8 | 0.0 | 0.859 | 0.878 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | CAL-101 | 3 | 72 | 3.2 | 3294.5 | 4010.0 | 1175.8 | 0.505 | 0.790 | 0.822 | 1.770 | BT549 CAL101 0 3 72 |
| BT-549 | Everolimus | 3 | 72 | 0.001 | 2531.3 | 3532.8 | 1175.8 | -3.0 | 0.621 | 0.717 | 1.587 | BT549 Everolimus 0 3 72 |